Samjin Pharmaceutical
CompanySouth Korea
Samjin Pharmaceutical develops 2 assets, the furthest approved (naloxone hydrochloride in opioid overdose). Mostly small molecule acting on OPRM1, OPRK1 and OPRD1; based in South Korea.
- 2
- Assets
- Furthest stage
- Approved
- 3
- Trials
- 19
- Signals
Pipeline
2Blocks opioid receptors, reversing opioid-mediated effects.
Approved, Small molecule, OPRM1, OPRK1, opioid overdose, overdose
Inhibits phosphodiesterase 5, increasing cyclic GMP signaling.
Phase 3, Small molecule, PDE5A, Alzheimer's disease, Partner
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms5
- Trials10
- Signals20
- Similar companies6